Discover 262 paid clinical trials in Delaware. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Delaware offers numerous clinical research opportunities, including paid studies for healthy volunteers and those with specific medical conditions. Major centers in Wilmington, Dover, and Newark are actively recruiting participants, offering access to emerging treatments and innovative medical care.
Filter
1
Filter results
Results: 262
Active & Responsive
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Get alerts for new trials in your area by subscribing now
Active & Responsive
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
for
Clinical Stage III Cutaneous Melanoma AJCC v8,
Location: Springfield MA, Saint Johnsbury VT, Lebanon NH,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05136196
Phase 2, Recruiting
Active & Responsive
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Positive Processes and Transition to Health (PATH)
for
Posttraumatic Stress Disorder, Major Depressive Disorder
Location: Newark DE, Cleveland OH, Seattle WA
Sponsor: Case Western Reserve University
Sex: All
Age: 18 - 65
Code: NCT06093906
Recruiting
Active & Responsive
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
for
Metastatic Head and Neck Squamous Cell Carcinoma,
Location: Boston MA, Providence RI, New York NY, Hackensack NJ,
Sponsor: Bicara Therapeutics
Sex: All
Age: 18+
Code: NCT06788990
Phase 2, Phase 3, Recruiting
Active & Responsive
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
for
PIK3CA Mutation, HER2- Negative Breast Cancer,
Location: Boston MA, New Haven CT, New York NY, Hackensack NJ,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06982521
Phase 3, Recruiting
Active & Responsive
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
for
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver,